NASDAQ (usa) arrow 6715.56 -12.11 -0.18%
FTSE 100 (london) arrow 7487.96 -5.12 -0.07%
DAX (german) arrow 13465.51 235.94 1.78%
NIKKEI 225 (japan) arrow 22420.08 408.47 1.86%
Hang - Seng (hong kong) arrow 28594.06 348.52 1.23%
NIFTY - 50 (india)
Straits Times (singapore) arrow 3391.61 17.53 0.52%
KOSPI (korea) arrow 2556.47 33.04 1.31%
All Ordinaries (australia) arrow 6005.30 28.90 0.48%
BOVESPA (brazil) arrow 74092.76 -215.73 -0.29%

Infinity Pharmaceuticals Inc (F: I3F)

 
I3F Technical Analysis
5
As on 11th Jul 2023 I3F STOCK Price closed @ 0.21 and we RECOMMEND Strong Sell for LONG-TERM with Stoploss of 0.89 & Strong Sell for SHORT-TERM with Stoploss of 0.95 we also expect STOCK to react on Following IMPORTANT LEVELS.
 
 

I3FSTOCK Price

Open 0.20 Change Price %
High 0.21 1 Day 0.03 16.67
Low 0.20 1 Week 0.03 16.67
Close 0.21 1 Month 0.07 50.00
Volume 48499 1 Year -0.87 -80.56
52 Week High 1.67 | 52 Week Low 0.09
 
F Germany Most Active Stocks
ENB 47.60 -0.92%
TEF 3.84 -0.52%
TEF 3.84 -0.52%
WHL 5150.00 -0.44%
WDI 0.05 -37.50%
WDI 0.05 -37.50%
WDI 0.05 -37.50%
WDI 0.05 -37.50%
WDI 0.05 -37.50%
TOE 0.02 0.00%
 
F Germany Top Gainers Stocks
0AI 11.30 14025.00%
0AI 11.30 14025.00%
SUE1 12.60 12500.00%
WPIA 6.22 871.88%
WPIA 6.22 871.88%
WPIA 6.22 871.88%
8S3B 1.73 620.83%
8S3B 1.73 620.83%
SY7P 0.07 600.00%
P9F1 1.75 326.83%
 
F Germany Top Losers Stocks
TINC 0.01 -99.92%
TINC 0.01 -99.92%
TINC 0.01 -99.92%
LDB 1.71 -92.57%
LDB 1.71 -92.57%
LDB 1.71 -92.57%
LDB 1.71 -92.57%
LDB 1.71 -92.57%
AETG 0.25 -91.61%
AETG 0.25 -91.61%
 
 
I3F
Daily Charts
I3F
Intraday Charts
Whats New @
Bazaartrend
I3F
Free Analysis
 
I3F Important Levels Intraday
RESISTANCE0.23
RESISTANCE0.22
RESISTANCE0.22
RESISTANCE0.22
SUPPORT0.20
SUPPORT0.20
SUPPORT0.20
SUPPORT0.19
 
I3F Forecast May 2024
4th UP Forecast0.79
3rd UP Forecast0.6
2nd UP Forecast0.49
1st UP Forecast0.37
1st DOWN Forecast0.05
2nd DOWN Forecast-0.07
3rd DOWN Forecast-0.18
4th DOWN Forecast-0.37
 
I3F Weekly Forecast
4th UP Forecast0.44
3rd UP Forecast0.37
2nd UP Forecast0.32
1st UP Forecast0.28
1st DOWN Forecast0.14
2nd DOWN Forecast0.10
3rd DOWN Forecast0.05
4th DOWN Forecast-0.02
 
I3F Forecast2024
4th UP Forecast3.27
3rd UP Forecast2.29
2nd UP Forecast1.68
1st UP Forecast1.08
1st DOWN Forecast-0.66
2nd DOWN Forecast-1.26
3rd DOWN Forecast-1.87
4th DOWN Forecast-2.85
 
 
I3F Other Details
Segment EQ
Market Capital 192619296.00
Sector Healthcare
Industry Biotechnology
Offical website >
 
I3F Address
I3F
 
I3F Latest News
 
Your Comments and Response on Infinity Pharmaceuticals Inc
 
I3F Business Profile
Infinity Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing novel medicines for people with cancer. Its product candidate is IPI-549, an orally administered clinical-stage immuno-oncology product candidate that inhibits the enzyme phosphoinositide-3-kinase-gamma, which is in Phase 1/1b clinical trials for the treatment of triple negative breast cancer, solid tumors, and ovarian cancer. The company has strategic alliances with Intellikine, Inc. to discover, develop, and commercialize pharmaceutical products targeting the delta and/or gamma isoforms of PI3K; Verastem, Inc. to research, develop, commercialize, and manufacture duvelisib and products containing duvelisib; and PellePharm, Inc. to develop and commercialize rights to its hedgehog inhibitor program, IPI-926, a clinical-stage product candidate, as well as collaboration agreements with Arcus Biosciences, Inc., F. Hoffmann-La Roche Ltd., and Bristol Myers Squibb Company. Infinity Pharmaceuticals, Inc. was incorporated in 2000 and is headquartered in Cambridge, Massachusetts. Address: 1100 Massachusetts Avenue, Cambridge, MA, United States, 02138
 
© 2005-2023 BazaarTrend.com All rights reserved.

Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service